Bio-Techne Corp
- Last sale
- Nov 6, 2026 · +0.17%
- Market cap
- $11.44B
- 157.09M shares
- Filings
- 1,054
Q1 2027−0.4% FY26 yoy
Q1 2027+147.8% FY26 yoy
Q1 2027+146.3% FY26 yoy
Q1 2027derived+2.6% FY26 yoy
Q1 2027+152.2% FY26 yoy
Q1 2027+63.2% FY26 yoy
- $11.44B
- 66.5×
- 9.3×
- 5.3×
- 2.69%
- 0.44%
Twelve months to Sep 30, 2026 · derived
Price
Nov 6, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2026 | 2026-06-30 | $1,215,039,000 | reported | |
| FY 2025 | 2025-06-30 | $1,219,635,000 | reported | |
| FY 2024 | 2024-06-30 | $1,159,060,000 | reported | |
| FY 2023 | 2023-06-30 | $1,136,702,000 | reported | |
| FY 2022 | 2022-06-30 | $1,105,599,000 | reported | |
| FY 2021 | 2021-06-30 | $931,032,000 | reported | |
| FY 2020 | 2020-06-30 | $738,691,000 | reported | |
| FY 2019 | 2019-06-30 | $714,006,000 | reported | |
| FY 2018 | 2018-06-30 | $642,993,000 | reported | |
| FY 2017 | 2017-06-30 | $563,003,000 | reported | |
| FY 2016 | 2016-06-30 | $499,023,000 | reported | |
| FY 2015 | 2015-06-30 | $452,246,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2026 | $49.92M | $41.68M | $91.59M | $0.32 | 157.06M sh | +1.0% | 34.8% |
| FY2025 | $50.39M | $275.73M | $326.12M | $0.32 | 155.55M sh | −1.9% | 127.1% |
| FY2024 | $50.42M | $80.04M | $130.46M | $0.32 | 158.60M sh | +0.3% | 55.3% |
| FY2023 | $50.29M | $19.56M | $69.85M | $0.32 | 158.17M sh | +303.4% | 32.3% |
| FY2022 | $50.19M | $160.95M | $211.14M | $0.32 | 39.21M sh | +0.3% | 75.3% |
Segments
LineFY2026ShareChange
Protein Sciences$874.62M72%+0.5%
Diagnostics and Spatial Biology$336.37M28%−2.9%
Diagnostics and Genomics———
Other Revenues from Business Held for Sale———
Total$1.22B
Biological products, except diagnostic substances
Bio-Techne Corp is the 9th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
EXELExelixis, Inc.$2.3B7.0%33.7%$17.0BQGENQiagen N.V.$2.1B5.7%20.3%$10.9BMRNAModerna, Inc.$1.9B39.9%145.2%$93.6BHALOHalozyme Therapeutics, Inc.$1.4B37.6%22.7%$11.5B
TECHBio-Techne Corp (this company)$1.2B0.4%15.0%$11.4B
NVAXNovavax Inc$1.1B64.7%39.2%$1.4BBCRXBiocryst Pharmaceuticals Inc$874.8M94.1%30.2%$2.0BRGENRepligen Corp$738.3M16.4%6.6%$10.7BALVOAlvotech$586.3M19.7%4.8%$1.5BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Bio-Techne Corp · CIK 842023 · Engraved from SEC EDGAR